### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, gemcitabine was added to the complementary list of the EML for use in treatment protocols for epithelial ovarian cancer. The relevant extract from TRS994 regarding the Expert Committee's consideration of treatment protocols for epithelial ovarian cancer is attached.